Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study

Gambichler, Thilo; Othlinghaus, Nick; Tomi, Nordwig S.; Holland‐Letz, Tim; Boms, Stefanie; Skrygan, Marina; Altmeyer, Peter; Kreuter, Alexander

doi:10.1111/j.1365-2133.2008.08984.x

Cited by 99 publications

(105 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As the DLQI or the EQ-5D-VAS have not been used for evaluating UV therapy in atopic dermatitis patients yet, comparison of the present results is difficult [42]. However, high time expenditure for a treatment, which must take place several times a week, and limitation in long-term effectiveness might add up to a low quality of life [16].…”

Section: Discussionmentioning

confidence: 99%

Therapeutic Benefits in Atopic Dermatitis Care from the Patients' Perspective: Results of the German National Health Care Study ‘Atopic Health'

Steinke

Langenbruch²,

Ständer³

et al. 2014

Dermatology

View full text Add to dashboard Cite

Background/Aims: Numerous therapies are recommended to treat atopic dermatitis. The German national health care study ‘Atopic Health' generated nationwide data on the care situation from the patients' perspective. Methods: Data for 1,678 adult patients were collected within a retrospective cohort study throughout the year 2010. Six scores to capture satisfaction with care, quality of life (Dermatology Life Quality Index, EQ-5D-VAS), therapeutic success and benefits (Patient Benefit Index) were analyzed using descriptive methods and analysis of variance. Results: 82.1% of patients were highly satisfied with their treatment. Topical corticosteroids and climate therapies were associated with the best success ratings. Quality of life was moderately impaired (mean Dermatology Life Quality Index 8.5 ± 6.5). 88.4% of the patients indicated a relevant therapeutic benefit (Patient Benefit Index ≥1) with significantly better scores for topical immunomodulating therapies and climate therapies. Conclusion: The most frequently applied therapies presented pleasant success and benefit ratings, even if quality of life could be improved for more than one third of patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Therapeutic Benefits in Atopic Dermatitis Care from the Patients' Perspective: Results of the German National Health Care Study ‘Atopic Health'

Steinke

Langenbruch²,

Ständer³

et al. 2014

Dermatology

View full text Add to dashboard Cite

show abstract

“…23---26 Some studies also used quality-of-life scales (Eczema Disability Index, 17 Sickness Impact Profile 6 ) and assessments of pruritus. 8,14,20,22,27 Cumulative dosage was an outcome measure in 1 study 19 and length of remission was used in 2 studies. 7,21…”

Section: Included Studiesmentioning

confidence: 99%

Phototherapy in Atopic Dermatitis: A Systematic Review of the Literature

Pérez‐Ferriols

Aranegui

Pujol-Montcusí

et al. 2015

Actas Dermo-Sifiliográficas (English Edition)

View full text Add to dashboard Cite

There is evidence for the use of narrow-band UV-B and UV-A1 phototherapy in moderate to severe atopic dermatitis. Evidence supporting the use of PUVA in atopic dermatitis is scarce and there is little information on the use of phototherapy in childhood. For the purpose of future studies, it would be advisable to use comparable criteria and scales for the evaluation of disease severity and patients, to standardize radiation methods, and to establish a minimum follow-up time.

show abstract

“…Akut AD'de kullanımı önerilen bu fototerapi yöntemini, çok daha yaygın olarak kullanılan dar bant UVB ile karşılaştıran çalışmalar da bulunmaktadır. Bu çalışmalardan birinde kronik AD'de dar bant UVB, orta doz UVA1'den daha etkili bulunurken (70), diğer iki çalışmada her iki tedavi yönteminin de eşit etkinliğe sahip oldukları gösterilmiştir (71,72).…”

Section: Atopik Dermatitte Fototerapiunclassified

Current Approach to Phototherapy Applications in Dermatology Practice: Part 2. Phototherapy in Vitiligo, Mycosis Fungoides, Atopic Dermatitis, Sclerosing Diseases and Psoriasis

Gençosmanoğlu¹

2017

tdd

View full text Add to dashboard Cite

Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study

Abstract: A 6-week course of NB-UVB and UVA1 phototherapy of AE resulted in significant clinical improvement. With regard to efficacy and tolerability, both phototherapeutic modalities may be considered comparably good.

Cited by 99 publications

References 34 publications

Therapeutic Benefits in Atopic Dermatitis Care from the Patients' Perspective: Results of the German National Health Care Study ‘Atopic Health'

Therapeutic Benefits in Atopic Dermatitis Care from the Patients' Perspective: Results of the German National Health Care Study ‘Atopic Health'

Phototherapy in Atopic Dermatitis: A Systematic Review of the Literature

Current Approach to Phototherapy Applications in Dermatology Practice: Part 2. Phototherapy in Vitiligo, Mycosis Fungoides, Atopic Dermatitis, Sclerosing Diseases and Psoriasis

Contact Info

Product

Resources

About